Incyte Corporation;H. Lee Moffitt Cancer Center and Research Institute, Inc.
发明人:
Holly Koblish,Gary Reuther
申请号：
US16783663
公开号：
US20200179364A1
申请日:
2020.02.06
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present application relates to treatment of myeloproliferative neoplasms using the JAK1/JAK2 inhibitor, ruxolitinib, in combination with a low dose of a Pim inhibitor, N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, wherein the combination is unexpectedly synergistic at a very low dose of the Pim inhibitor.
